Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | SWI:SNF matrix associated | 0.00107271 | 0.5 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.00107271 | 0.5 | 0.5 |
Toxoplasma gondii | SWIB/MDM2 domain-containing protein | 0.00107271 | 0.5 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.00107271 | 0.5 | 0.5 |
Loa Loa (eye worm) | SWIB/MDM2 domain-containing protein | 0.00107271 | 0.5 | 0.5 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.00107271 | 0.5 | 0.5 |
Schistosoma mansoni | brg-1 associated factor | 0.00107271 | 0.5 | 0.5 |
Onchocerca volvulus | 0.00107271 | 0.5 | 0.5 | |
Echinococcus granulosus | SWI:SNF matrix associated | 0.00107271 | 0.5 | 0.5 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.00107271 | 0.5 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.00107271 | 0.5 | 0.5 |
Chlamydia trachomatis | DNA topoisomerase I | 0.00107271 | 0.5 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.00107271 | 0.5 | 0.5 |
Echinococcus multilocularis | Upstream activation factor subunit UAF30 | 0.00107271 | 0.5 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.00107271 | 0.5 | 0.5 |
Chlamydia trachomatis | SWIB complex protein | 0.00107271 | 0.5 | 0.5 |
Plasmodium vivax | SWIB/MDM2 domain-containing protein, putative | 0.00107271 | 0.5 | 0.5 |
Brugia malayi | brahma associated protein 60 kDa | 0.00107271 | 0.5 | 0.5 |
Echinococcus granulosus | Upstream activation factor subunit UAF30 | 0.00107271 | 0.5 | 0.5 |
Brugia malayi | brahma associated protein 60 kDa | 0.00107271 | 0.5 | 0.5 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.00107271 | 0.5 | 0.5 |
Toxoplasma gondii | DNA topoisomerase domain-containing protein | 0.00107271 | 0.5 | 0.5 |
Brugia malayi | SWIB/MDM2 domain containing protein | 0.00107271 | 0.5 | 0.5 |
Loa Loa (eye worm) | brahma associated protein | 0.00107271 | 0.5 | 0.5 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.00107271 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 3.6 uM | Concentration required to reduce the growth of human Jurkat cells to 50% of control cultures | ChEMBL. | 9258370 |
IC50 (functional) | = 3.6 uM | Concentration required to reduce the growth of human Jurkat cells to 50% of control cultures | ChEMBL. | 9258370 |
IC50 (functional) | = 3.9 uM | Concentration required to reduce incorporation of [3H]-TdR in drug-treated cultures of intracellular Leishmania major to 50% of controls | ChEMBL. | 9258370 |
IC50 (functional) | = 3.9 uM | Concentration required to reduce incorporation of [3H]-TdR in drug-treated cultures of intracellular Leishmania major to 50% of controls | ChEMBL. | 9258370 |
Index | = -2.74 | Lipophilicity index (substitution method) | ChEMBL. | 9258370 |
Therapeutic index (ADMET) | = 0.9 | In vitro therapeutic index calculated as the IC50 ratio of Jurkat cells to that of Leishmania major. | ChEMBL. | 9258370 |
Therapeutic index (ADMET) | = 0.9 | In vitro therapeutic index calculated as the IC50 ratio of Jurkat cells to that of Leishmania major. | ChEMBL. | 9258370 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 9258370 | |
Leishmania major | ChEMBL23 | 9258370 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.